LT5589B - N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas - Google Patents

N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas Download PDF

Info

Publication number
LT5589B
LT5589B LT2008075A LT2008075A LT5589B LT 5589 B LT5589 B LT 5589B LT 2008075 A LT2008075 A LT 2008075A LT 2008075 A LT2008075 A LT 2008075A LT 5589 B LT5589 B LT 5589B
Authority
LT
Lithuania
Prior art keywords
pyrrolidinone
phenyl
carbamoylmethyl
compound
formula
Prior art date
Application number
LT2008075A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2008075A (en
Inventor
Grigory Veinberg
Maksim VORONA
Liga Zvejniece
Aleksandrs Chernobrovijs
Ivars Kalvinsh
Ligita KARINA
Maija DAMBROVA
Original Assignee
Akciju Sabiedriba "Olainfarm", ,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akciju Sabiedriba "Olainfarm", , filed Critical Akciju Sabiedriba "Olainfarm", ,
Publication of LT2008075A publication Critical patent/LT2008075A/xx
Publication of LT5589B publication Critical patent/LT5589B/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
LT2008075A 2006-03-16 2008-09-22 N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas LT5589B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-06-45A LV13630B (en) 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone

Publications (2)

Publication Number Publication Date
LT2008075A LT2008075A (en) 2009-06-25
LT5589B true LT5589B (lt) 2009-08-25

Family

ID=38461010

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2008075A LT5589B (lt) 2006-03-16 2008-09-22 N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas

Country Status (21)

Country Link
US (2) US9102615B2 (fr)
EP (1) EP2013166B1 (fr)
CN (1) CN101448786A (fr)
AT (1) ATE460396T1 (fr)
CA (1) CA2647206C (fr)
CY (1) CY1110170T1 (fr)
DE (1) DE602007005244D1 (fr)
DK (1) DK2013166T3 (fr)
EA (1) EA014668B1 (fr)
EE (1) EE05536B1 (fr)
ES (1) ES2342024T3 (fr)
GE (1) GEP20104915B (fr)
HR (1) HRP20090524C1 (fr)
LT (1) LT5589B (fr)
LV (1) LV13630B (fr)
ME (1) ME01192B (fr)
PL (1) PL2013166T3 (fr)
PT (1) PT2013166E (fr)
SI (1) SI2013166T1 (fr)
UA (1) UA96440C2 (fr)
WO (1) WO2007104780A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV14346B (lv) * 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
EP2694474A1 (fr) * 2011-03-11 2014-02-12 Grindeks Enantiomère 4r,5r du 2-(5-méthyl-2-oxo-4-phénylpyrrolidine-1-yl) acétamide à activité nootropique
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
CN104350063B (zh) 2012-05-08 2018-01-05 尼科斯眼药公司 疏水性治疗剂的制剂、其制备方法及应用
TW201408294A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
TW201408293A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
LV15015B (lv) 2013-12-13 2015-12-20 Olainfarm, A/S 3-karboksi-4-(R)-fenilpirolidin-2-ona sāls un tā pielietošana
LV15016B (lv) * 2013-12-18 2016-01-20 Olainfarm, A/S N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas
EP2891491A1 (fr) 2014-01-03 2015-07-08 Merz Pharma GmbH & Co. KGaA Utilisation de (r) -phénylpiracétame pour le traitement de troubles du sommeil
LV15072B (lv) 2014-05-14 2016-09-20 Olainfarm, A/S Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
EP3127539A1 (fr) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Utilisation de 2- (5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl) -acétamide dans le traitement de crises d'épilepsie
WO2024049236A1 (fr) * 2022-08-31 2024-03-07 고려대학교 산학협력단 Dérivé de gamma lactame chiral ou sel pharmaceutiquement acceptable de celui-ci, et sa méthode de préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
RU2232578C1 (ru) 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2289404C1 (ru) * 2005-04-06 2006-12-20 ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.MASHKOVSKY: "Medicinal drugs", pages: 70 - 79

Also Published As

Publication number Publication date
EP2013166B1 (fr) 2010-03-10
LT2008075A (en) 2009-06-25
EA014668B1 (ru) 2010-12-30
DK2013166T3 (da) 2010-07-05
SI2013166T1 (sl) 2010-07-30
ME01192B (fr) 2012-12-20
ES2342024T3 (es) 2010-06-30
EE05536B1 (et) 2012-04-16
HRP20090524A2 (hr) 2009-12-31
US20150216846A1 (en) 2015-08-06
GEP20104915B (en) 2010-03-10
EP2013166A2 (fr) 2009-01-14
US20100022784A1 (en) 2010-01-28
EE200800063A (et) 2008-12-15
HRP20090524C1 (hr) 2017-03-10
CA2647206C (fr) 2011-09-27
UA96440C2 (ru) 2011-11-10
CY1110170T1 (el) 2015-01-14
US9382203B2 (en) 2016-07-05
ATE460396T1 (de) 2010-03-15
CA2647206A1 (fr) 2007-09-20
WO2007104780A2 (fr) 2007-09-20
HRPK20090524B3 (hr) 2012-12-31
DE602007005244D1 (de) 2010-04-22
EA200801978A1 (ru) 2009-04-28
US9102615B2 (en) 2015-08-11
CN101448786A (zh) 2009-06-03
PT2013166E (pt) 2010-06-09
WO2007104780A3 (fr) 2007-11-29
LV13630B (en) 2007-12-20
PL2013166T3 (pl) 2010-08-31

Similar Documents

Publication Publication Date Title
LT5589B (lt) N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas
TWI286132B (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
JPS62190160A (ja) (−)−ベンツヒドリルスルフイニルアセトアミド及びその製法
Baures et al. Crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
US9714239B2 (en) N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders
HRP20120166T1 (hr) Supstituirane n-bipirolidinuree i njihova upotreba u terapiji
JP5377473B2 (ja) 高純度の2,4’−ジメチル−3−ピペリジノ−プロピオフェノン(トルペリゾン)、これを含む医薬品組成物の製造法、並びにトルペリゾン含有活性物質組成物
FI934752A0 (fi) Substituerade kinuklidiner
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
RU2008123376A (ru) Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов
DE60219954D1 (de) Neue Indol-2-on Derivate
Galman et al. Biomimetic synthesis of 2-substituted N-heterocycle alkaloids by one-pot hydrolysis, transamination and decarboxylative Mannich reaction
AP1016A (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as opioid kappa receptor agonists.
EP4125840A1 (fr) Composés destinés à être utilisés dans le traitement de synucléinopathies
TWI291349B (en) Benzyloxy derivatives as MAOB inhibitors
Wang et al. Synthesis and immunosuppressant activity of pyrazole carboxamides
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
KR20210014164A (ko) 히스타민-3 수용체 역작용제에 의한 치료 방법
US20230016922A1 (en) Visible-light mediated organophotoredox catalytic deuteration of aromatic and aliphatic aldehydes
US11584710B2 (en) Compounds for treating infections
ATE315023T1 (de) Aminoalkylpyrrolidine als serotoninrezeptorliganden sowie diese enthaltende zusammensetzungen, pharmazeutische verwendungen und methoden zu deren synthese
LV14346B (lv) 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
TW410217B (en) Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US6060516A (en) N1 -propargylhydrazines, N2 -propargylhydrazines and their analogs for the treatment of depression, anxiety and neurodegeneration
CHANG et al. New Synthesis of Β-Aryl-Gaba Drugs

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20160315